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Recently, no causal relationship between hepatitis G 
virus (HGV) and acute hepatitis could be established 
in patients living in the USA [l]. Furthermore, HGV 
genome detection was common in volunteer healthy 
blood donors [2]. These features raise questions about 
the possible implication of HGV in hepatitis. Since 
one identification of HGV (GBV-C virus) was initially 
performed from a specimen originating from West 
Africa [3], we evaluated the prevalence of HGV in- 
fection in African patients with well-documented 
chronic hepatitis. 
One hundred patients living in Senegal, and suffer- 
ing from chronic hepatitis with transaminase elevation 
and confirmed by liver biopsy, were analyzed for the 
blood markers of hepatitis viruses B (I-BV) and C 
(HCV) involved in chronic evolution. Fifty healthy, 
age-matched individuals offering their blood for trans- 
fusion were used as controls. HGV RNA was detected 
in serum by a domestic reverse transcription (RT)- 
nested polymerase chain reaction (PCR), with primers 
located in the NS3 region of the viral genome. The 
outer primers were GBV-C virus consensus oligo- 
nucleotide primers gbvc-sl and gbvc-a1 [4], and the 
inner primers were gbvc-26 (sense, 5'-GGN-VGV- 
CAY-CTB-GTB-GTR-TTC-3') and gbvc-116 (anti- 
sense, 5'-RCT-GTC-YTT-VCC-CCT-RTA-3'), in 
which R denotes A or G and Y denotes C or T. 
All primers were purchased from Genset Oligos SA 
(France). Outer amplification was performed by 'touch- 
down' [5] PCR for 40 cycles (94"C, 30 sec; 55"C, 30 
min, decreasing by 1°C per cycle; 72"C, 60 sec), 
followed by 15 cycles (94"C, 30sec; 40"C, 30sec; 
72"C, 60 sec), with a final 15-sec extension (72OC). 
The inner PCR consisted of 40 cycles, includlng five 
cycles at 94°C for 45 sec; 45°C for 45 sec and 72°C 
for 60 sec, followed by five cycles at 94°C for 45 sec; 
48°C for 45 sec and 72°C for 60 sec, with a subsequent 
30 cycles at 94°C for 45 sec, 5OoC for 45 sec and 72°C 
for 60 sec, and a final 15-min elongation (72°C). The 
specificity of our RT-nested PCR was verified by probe 
hybridlzation (a gift of Abbott Laboratories, USA). 
Among patients, 92 had serologic evidence of past 
HBV infection (anti-HBc positivity) (Table 1); among 
those, 45 were HBs Ag positive. Since mutations within 
the X-gene may suppress expression of HBV and there- 
fore hinder HJ3s Ag detection by immunoenzymatic 
tests [6], all sera from patients with anti-HEk antibodies 
without H B s  Ag were also submitted to PCR for HBV 
DNA; HBV DNA was never found in our patients in 
the absence of H B s  Ag. Four patients were seropositive 
for HCV infection and viremic, as assessed by positive 
RT-PCR for HCV RNA in plasma (HCV Detection 
kit Amplicor, Roche Diagnostic Systems, Basel, 
Switzerland); all were HBs Ag negative and anti-HBc 
positive. Among controls, 46 were anti-HBc positive, 
four were HBs Ag positive, and seven were seropositive 
for HCV infection. Concerning the prevalence of 
HGV, nine (9%) patients had HGV RNA in their 
serum, whereas six (12%) blood donors were positive 
(not significant). All patients infected by HGV were 
seronegative for HCV and HBs Ag negative; six of 
them were anti-HBc positive. 
In our series of Senegalese patients with chronic 
hepatitis, 49% were related to identified viral hepatitis, 
mostly due to HJ3V (45%), and rarely to HCV (4%). 
For HGV, there was an identical rate of detectable 
viremia in patients with suspected non-B, non-C 
hepatitis, and in healthy controls. We conclude that 
HGV infection does not constitute a cause of chronic 
non-B, non-C hepatitis in West Africa. These obser- 
vations are in keeping with recent reports casting doubt 
on the disease-causing role of HGV, and suggest a lack 
of pathogenicity for HGV. 
Table 1 Serologic or molecular makers for hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis G virus (HGV) 
infections in Senegalese patients with chronic hepatitis and in healthy age-matched controls 
HBV markers 
Ab to HBc HRs Ag 
RT-PCR 
Ah to HCV for HGV P I  
100 92 45 4 9 Chronic hepatitis 
Controls 5 0 
Ah, antibodies; Ag, antigen. 
46 4 7 6 
222 
Concise Communications 223 
Acknowledgment 
Grant support was provided by Dtltgation la 
Recherche clinique/AP-HP. 
L. Bdlec'", AT Cancrd', A. Si Mohamed', 
K .  Habibatou3, M. Matta ', 
J. Pillot4 and A .  Diallo3 
Laboratoire de Virologie, 
Hapital Broussais, Paris, France; 
%stitut Pasteur de Dakar, Stntgal; 
31nsti~t d'HygiPne de Dakar, Stntgal; 
4Service de Microbiologie, 
Hapital Antoine BeclPre, 
Clamart, France 
'Tel: +33 1 43 95 80 53 Fax: +33 1 43 95 80 55 
Accepted 26 November 1997 
References 
1. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E 
hepatitis in the United States and the role of hepatitis G virus 
infection. N Engl J Med 1997; 336: 741-6. 
2. Alter MJ, Nakatsuji Y, Melpolder J, et al. The incidence of 
transfusion-associated hepatitis G virus infection and its 
relation to liver dlsease. N Engl J Med 1997; 336: 747-54. 
3. Simons JN, Leary TE Dawson GJ, et al. Isolation of novel 
virus-like sequences associated with human hepatitis. Nature 
Med 1995; 1: 564-9. 
4. Leary TP, Muerhoff AS, Simons JN, et al. Consensus 
oligonucleotide primers for the detection of GB virus C in 
human cryptogenic hepatitis. J Virol Methods 1996; 56: 
5. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 
'Touchdown' PCR to circumvent spurious priming during 
gene amplification. Nucleic Acids Res 1991; 19: 4008. 
6. Uchda T, Gotoh K, Shikata T. Complete nucleotide 
sequences and the characteristics of two hepatitis B virus 
mutants causing serologically negative acute or chronic 
hepatitis B. J Med Virol 1995; 45: 247-52. 
119-21. 
Diagnosis of disseminated toxoplasmosis by PCR analysis 
of ascitic fluid in a patient with haematologic malignancy 
Clin Microbiol Infect 1998; 4: 223-224 
%xoplasma gondii can cause severe life-threatening 
infections in immunocompromised patients. Involve- 
ment of lung or central nervous system occurs alone or 
in association with dissemination of the parasite to 
other body parts [I]. Acute infection often results 
h m  the reactivation of dormant T gondii bradyzoites 
contained within cysts after a primary infection, and 
serum antibodies may be unreliable in differentiating 
between active and chronic infection. To overcome 
this difficulty, detection of T. gondii DNA by PCR 
has been applied to blood, bronchoalveolar lavage and 
cerebrospinal fluid samples [2,3]. We report a case 
of active toxoplasmosis that was diagnosed by PCR 
analysis of the ascitic fluid in a patient treated with 
pyrime thamine. 
In September 1995, a 50-year-old man with 
idopathic myelofibrosis and evidence of past T gondii 
infection (serum IgG antibody titer at 50 I U / d  with 
no specific IgM) presented a serologic toxoplasmic 
reactivation with a 20-fold increase in anti-?: gondii 
IgG and appearance of specific IgA (index = 20, 
Platelia Sanofi Diagnostic Pasteur) without any clinical 
evidence of disease. Upon treatment with pyri- 
methamine (100 mg/day) and sulfadiazine (4 g/day), 
IgG antibodies returned to their initial values and IgA 
disappeared. Sulfadiazine was thus discontinued after 6 
weeks of treatment, and the patient was maintained on 
pyrimethamine (100 mg/day until June 1996 and then 
50 mg/day) as secondary prophylaxis. In September 
1996, the patient was admitted with significant spleno- 
megaly and ascites. Osteomedullary biopsy showed 
diffuse myelofibrosis without signs of blast crisis. A 
splenectomy was performed. Pathologic examination 
of the spleen revealed acute leukemic transformation 
and local infarction. A few days after splenectomy, 
the patient presented with fever and relapse of the 
ascites. Analysis of the peritoneal fluid showed a total 
protein content of 39 g/L, a leukocytosis of 1.8 x 106/L 
(granulocyte neutrophils 77%; macrophages, 23%), and 
rare peritoneal cells. No malignant cells were observed. 
Peritoneal cultures were negative for bacteria, f h g i  
and viruses. Toxoplasmic serologic values remained 
unchanged. T gondii DNA was detected in the ascitic 
fluid by PCR-ELISA (Boehringer Mannheim), using a 
technique that targets the B1 gene of T gondii and 
includes dUTP and uracyl DNA glycosylase to prevent 
carryover contaminations, as well as a positive internal 
control to avoid false negative results due to PCR 
inhibitors [4]. Subsequent PCR analysis of the spleen 
parenchyma that had been frozen at -8OOC after 
splenectomy was also positive for Tgondii. The patient's 
clinical status improved when therapy with sulfadiazine 
(4 g/day) and pyrimethamine (100 &day) was initiated. 
His condition remained stable and he was treated as 
an outpatient with sulfadiazine, pyrimethamine and 
hydroxycarbamide (1 g/day) . 
Serologic screening for anti-T gondii antibodies is 
part of the regular follow-up scheme for immuno- 
compromised patients at our institution. Since the 
appearance of specific IgA may occur prior to clinical 
infection in immunocompromised patients [5], and 
given the IgA index of the sample (20 is the maximurn 
value with the Platelia Sanofi Diagnostic Pasteur assay), 
